High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.
The company recovered 186 million euros after it “largely completed the U.S. tariff refund process” in the quarter, CEO Roy ...
Challenges in the electrophysiology and Watchman businesses led the medtech company to cut its sales and earnings per share ...
Sales in Johnson & Johnson’s Abiomed business declined in the second quarter due to procedure volume pressures related to its Impella device.